The clonality of ipsilateral breast tumor recurrences (IBTR) after breast-conserving therapy (BCT) was established using a polymerase chain reaction-based allelic imbalance assay of microsatellite loci to compare tumor suppressor gene alteration patterns. Methods: The clonality of IBTRs relative to the initial invasive carcinomas were analyzed using a polymerase chain reaction-based allelic imbalance assay in 57 patients treated with BCT, including both whole breast irradiation and accelerated partial breast irradiation. Results: Thirty-four IBTRs (60%) were clonally related to the initial carcinoma and 23 (40%) were clonally different. Clonally related IBTRs were more frequently higher grade (70% vs. 32%, P ϭ 0.019) and developed sooner after initial treatment (mean time interval to IBTR was 5.1 years in clonally related versus 9.3 years in clonally different cases ͓P ϭ 0.002͔). Twelve patients subsequently developed distant metastases, of which 9 (75%) had clonally related IBTRs. Clinical IBTR classification and molecular clonality assay results differed in 44% of all cases. The proportion of IBTRs that were clonally related at 5, 10, and 15 years after BCT were 82%, 48%, and 33%, respectively. Conclusions: This analysis demonstrates the inaccuracy of clinically establishing the clonality of most IBTRs. Clonally related IBTRs occurred sooner than clonally different IBTRs, were more frequently associated with the development of distant metastases and had a worse prognosis. Molecular clonality assays provide a reliable means of identifying patients who may benefit from aggressive systemic therapy at the time of IBTR and provide an accurate assessment of the efficacy of various forms of local therapy.
T he success of breast-conserving therapy (BCT) has resulted in the dilemma of how best to manage disease recurrence within a previously irradiated breast. Ideally, ipsilateral breast tumor recurrences (IBTRs) would be classified as either true recurrences (TRs) of the treated malignancy or new primary carcinomas. If new primary tumors were proven to have a better prognosis compared with TRs, particularly as related to the risk of systemic recurrence, patient management might be significantly altered. 1 Unfortunately, none of the following factors have consistently succeeded in distinguishing TRs and new primaries: location of breast recurrence, tumor histology, flow cytometry, or time to IBTR. The result is potentially inaccurately reported rates and patterns of recurrence. Some authors have suggested that the greater the time interval from initial treatment to IBTR, the better the prognosis, but data are not reproducible across all studies. 2 Therefore, no consistent clinical, pathologic, or treatment-related variables can precisely define the type of IBTR.
Microsatellites are polymorphic, repetitive units of base pairs found within nuclear and organelle DNA throughout the genome. Allelic imbalance (AI), or the loss of 1 microsatellite allele as determined by loss of heterozygosity (LOH), is common in the hypermutable regions of DNA found in tumor suppressor genes of carcinoma cells. 3, 4 The polymerase chain reaction (PCR) technique using primers to flank microsatellite loci and the fluorescent capillary electrophoresis procedure are well-established methods to accurately identify microsatellite LOHs in formalin-fixed, paraffinembedded tissue. 5, 6 The LOH mutation pattern is a unique characteristic of a carcinoma, with the composite pattern of LOH gene mutations serving as a DNA fingerprint of the neoplasm. Comparison of the PCR-based LOH mutation patterns can reliably establish the clonality of one carcinoma relative to another. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] An LOH mutation pattern comparison using primers targeted to frequently deleted tumor suppressor genes is an ideal method for accurately distinguishing if an IBTR after definitive therapy represents a new primary versus a recurrence of the index lesion. This IBTR data could potentially define the efficacy of local radiation therapy modalities (whole breast vs. partial breast irradiation). Furthermore, LOH outcomes would help establish the importance of clinical, pathologic, or treatment-related factors associated with local control, as well as the prognosis and management of recurrences.
In this updated analysis, we established the clonality of initial invasive carcinomas and IBTRs post-BCT using LOH pattern comparisons to accurately identify failure patterns over time, assess treatment efficacy, and better define prognosis and the resultant implications for future treatment of IBTRs.
MATERIALS AND METHODS
Materials and methodology have previously been reported. 17 This study was reviewed and granted approval by the William Beaumont Hospital Human Investigation Committee. Patients with AJCC stage I/II invasive breast carcinoma treated with BCT who developed an IBTR and had no distant metastases (DM) prior to the IBTR were analyzed. Cases with biopsied IBTRs between January 1980 and June 2004 were selected for this analysis.
Although an initial attempt was made to analyze a consecutive series of cases, approximately 80% of patients with IBTRs and available tissue blocks were found to be unsuitable for genetic analysis. Reasons for exclusion included: block destruction by vermin, tissues fixed in Bouin's or B5 solutions, tissue blocks sent to academic institutions and not returned, mold overgrowth, or lack of available nonradiated normal tissue.
IBTRs were treated by mastectomy in most cases. Recorded IBTR factors included IBTR diagnosis date, carcinoma morphology, carcinoma grade, and hormone receptor status when available. Recorded factors in DM surgical specimens included DM diagnosis date, location of DM, carcinoma morphology, and carcinoma grade.
Study Population Characteristics
The 57 cases in the study population consisted of 48 patients treated with whole breast irradiation (WBI) and 9 treated with accelerated partial breast irradiation (APBI). All patients underwent, at minimum, an excisional biopsy achieving gross total resection of tumor. A level I-II axillary lymph node dissection was performed in all patients at initial diagnosis. Systemic therapy was administered according to the standard of care at the time of diagnosis, by the treating medical oncologist. WBI consisted of tangential 4 MV, 6 MV, or mixed 6-and 18-MV photon beams to a median dose of 45 Gy (range, 44 -50.4 Gy) plus a biopsy cavity boost for a median cumulative dose to Ͼ60 Gy. 18 The APBI technique has been previously reported. 19 All 9 APBI patients received brachytherapy. Eight patients received interstitial implants delivering either 5000 cGy in 96 hours (low dose rate brachytherapy, n ϭ 6) or 3200 to 3400 cGy in 8 to 10 fractions (high-dose rate brachytherapy, n ϭ 2). One patient was treated with MammoSite brachytherapy, receiving 3400 cGy in 10 fractions. 20
Molecular Clonality LOH Assay
A detailed description of the molecular clonality assay technique performed can be found in previous publications. 21, 22 Slides of the initial carcinoma and IBTR carcinoma were reviewed and foci of invasive or metastatic carcinoma with minimal inflammatory cells were carefully outlined on the slide. Tissues from the corresponding blocks were carefully microdissected using the outlined area on the slide as a template. All tissue was immediately placed in clean, 1.5-mL xylene-filled Eppendorf tubes.
Prior to study, all primers were tested and validated in-house. The primers were prepared and labeled with fluorescent dyes and in turn used to flank microsatellite regions of known tumor suppressor gene loci. Two separate, distinct allelic peaks were required for a marker to be classified as informative. In informative markers, the allele ratio of each carcinoma was compared with the ratio of normal tissue. LOH was defined as a Ն50% reduction in 1 of the 2 alleles in an invasive carcinoma compared with normal. Using the ratio of normal alleles as baseline, LOH was considered present if the ratio in the carcinoma was Ϯ50% the ratio of normal. A LOH mutation grid in each initial and IBTR carcinoma was constructed and mutation patterns of the 2 carcinomas were compared. The confidence level for each carcinoma clonality relationship determination was quantified using the mathematical formulas by Sieben et al. 23 The probability of obtaining the 2-LOH patterns was calculated twice: once assuming the initial and IBTR carcinoma were clonally different neoplasms, and once assuming the IBTR was genetically related to the initial carcinoma. Lastly, the likelihood ratio (LR) that the initial and IBTR carcinomas were clonally related was calculated. A high LR value (generally xEϩ02 or greater) reflected a high probability the initial and IBTR carcinomas were genetically related whereas a low LR value (generally less than xEϪ04) reflected a high probability the initial and IBTR carcinomas were clonally different, ie, the IBTR was an unrelated, second-primary carcinoma. 21, 22 Clinical Assessment of the Type of IBTR All IBTRs were evaluated separately (without knowledge of the results of the molecular clonality analyses) using clinical and, infrequently, pathologic criteria to distinguish new primary cancers from TRs. IBTRs were subdivided into TR/marginal miss (MM) versus elsewhere (E) failures based on the location of the recurrence within the breast (Harvard criteria). 24 TR/MM failures were considered to represent a recurrence of the original primary, whereas E failures designated new, second breast primaries. The distinction between TR/MM and E failures was generally based on tumor location, with other factors minimally influential (histology, flow cytometry, etc). If tumor recurrence location was equivocal (located several centimeters from the biopsy cavity but still technically within the same quadrant or midline and equidistant from 2 or more quadrants), tumor histology was used as the primary factor for IBTR classification (TR/MM vs. E). In 2 cases, IBTR clinical classification could not be established.
Statistical Methods
The estimated likelihood of events for disease-free survival (DFS), overall survival (OS), cause-specific survival (CSS), and distant metastasis free survival were calculated using the Kaplan-Meier method. 25 OS was based on death from any cause. CSS was defined as death attributed to breast cancer. Distant metastasis free survival was defined as any event attributable to distant recurrences. DFS was defined as any event attributed to breast cancer (ie, local, regional, or distant recurrence). All time intervals were calculated from the date of IBTR. The statistical significance of differences between treatment groups was calculated using the log-rank test. Association of categorical variables within treatment groups was analyzed using Fisher 2-tailed exact test. Statistically significant differences between 2 sample means for continuous variables were analyzed using t tests. A 2-tailed P value of 0.05 was considered to be statistically significant for all tests. Statistical analyses were performed using SYSTAT version 11.0 (Systat Software, Inc., Richmond, CA).
The median follow-up for all patients was 10.7 years (range, 1.2-20.4 years). Ninety percent of patients were followed for a minimum of 5 years from the date of initial diagnosis, whereas 61% were followed for more than 10 years. The median follow-up time from IBTR was 2.1 years (range, 0.0 -16.9 years). Thirty-two percent of patients were followed greater than 5 years since IBTR; 14% were followed greater than 8 years.
RESULTS

IBTR Molecular Clonality Determination
Patient-, tumor-, and treatment-related characteristics of the study population are presented in Table 1 . None of these characteristics were associated with the type of IBTR. On the basis of the comparison of the complete LOH mutation pattern in the initial and IBTR invasive carcinomas, more recurrences were clonally analogous. Specifically, 34 of the 57 IBTRs (60%) were clonally related to the initial carcinomas, whereas 23 (40%) were clonally distinct, second primary neoplasms. After WBI, 28 of the 48 (58%) IBTRs were clonally related; after APBI, 6 of 9 (67%) IBTRs were clonally related (P ϭ nonsignificant).
Characteristics of the Type of IBTR
The mean interval from RT completion to IBTR was 5.1 years (range, 0.6 -17.4) in patients with clonally related IBTRs versus 9.3 years in patients with clonally distinct IBTRs (P ϭ 0.002) ( Table 2) . Twelve patients developed DM following IBTR. Nine of these 12 patients had clonally related IBTRs. The 5-year DFS was 64% for those with clonally related IBTRs versus 84% for clonally distinct IBTRs (P ϭ 0.5) ( Table 3 ). The 5-year OS and CSS for patients with clonally related versus clonally distinct IBTRs was 70% versus 86%, (P ϭ 0.15). Age (categorical or continuous), grade, nodal status, and receipt of systemic therapy were not statistically significant predictors of improved DFS or CSS. Neither the form of local management at recurrence or addition of systemic chemotherapy impacted survival.
Clinical Versus Molecular Clonality Comparisons
The IBTR clinical (TR/MM or E) classification differed from the molecular clonality classification in 24 of 55 patients (44%) ( Table 2 ). Of the 33 IBTRs that were clinically classified as TR/MM failures, 12 (36%) were found to be clinically distinct new primary carcinomas upon PCR analysis. Of the 22 IBTRs that were clinically classified as E failures, 12 (55%) were found to be clonally related IBTRs. Differences between the clinical IBTR classification and the molecular clonality assay were not statistically significant (P ϭ 0.5).
Patterns of Failure Over Time
Differences in the type of IBTRs (clonally related vs. clonally distinct) that developed over time were studied. As evident in Table  4 , the percentage of clonally related IBTRs decreased with time, whereas the percentage of clonally distinct IBTRs increased with time. The proportion of IBTRs that were clonally related at 5, 10 and 15 years after BCT were 82%, 48%, and 33%, versus clonally distinct 18%, 52%, and 67%, respectively (P ϭ 0.015). The proportion of IBTRs determined to be clonally related after WBRT at 5, 10, and 15 years were 79%, 50%, and 37% versus clonally distinct 21%, 50% and 63%, respectively (P ϭ 0.05). A similar pattern was demonstrated in the APBI group, although the results were not statistically significant.
DISCUSSION
The comparison of the gene alteration patterns using markers of frequently deleted tumor suppressor genes is a well-established method for determining the clonality of 2 breast carcinomas. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In this updated analysis, the technique was applied to 57 cases of invasive carcinoma treated with BCT in which an IBTR occurred. Of these 57 cases, 34 (60%) had the same or an almost identical pattern of genetic mutations as the corresponding initial carcinoma, indicating they were genetically related, persistent neoplasms. Twenty-three IBTRs (40%) had a different and unique mutation pattern that was not present in the corresponding initial invasive carcinoma, indicating they were de novo, second primary carcinomas. As in our previous work, the molecular clonality designation of the type of IBTR differed from the clinical determination in a substantial number of cases (44%). The mean time interval to IBTR 
Molecular Clonality Assay: Rationale and Utility
Briefly, microsatellites are ideal for PCR-based assays because of their ubiquity in the human genome, the relative ease with which they are amplified, and their extreme polymorphism. Microsatellites that are linked to tumor suppressor genes have proven particularly useful, as the loss of 1 allele in 1 or more tumor suppressor genes frequently is a harbinger of malignant transformation. Because this form of gene alteration, termed an AI, involves a different set of microsatellite loci in unrelated tumors and a similar set of loci in related primary and recurrent tumors, the comparison of the gene alteration profiles of 2 tumors can be used to establish their relationship. The observed patterns of AI from a panel of microsatellites involving a pair of tumors usually provide a direct and unequivocal indication of whether the neoplasms are related clonally.
The utility of this technique has proven it's efficacy in assessing clonality among a variety of distinct tissue types, including melanoma; 26 carcinomas of the ovary, 27 lung, 28 and liver; 29 and invasive breast carcinoma. 15 This technique is also being explored at our own institution for recurrent prostate carcinomas. Because PCR-based AI assays can be performed easily on formalin-fixed, paraffin embedded tissue samples, the approach is ideally suited for use in routine clinical practice where recurrent disease is common and the necessity for molecular analysis is not always anticipated in advance.
The importance of accurately establishing the type of IBTR following BCT has been the subject of numerous publications. 30 The advantages of definitively identifying the type of IBTR are numerous and include (a) defining the true efficacy of a particular type of RT (ie, WBI vs. APBI), (b) establishing the importance of various clinical, pathologic, or treatment-related factors on local tumor control, and (c) helping to define the prognosis of an IBTR and the optimal treatment strategy. An objective characterization of recurrence is favored over historically employed approaches consisting of histopathologic comparison of tissue specimens, proximity to site of initial disease, flow cytometry, and the duration of time since the initial diagnosis. Such methodologies have proven difficult to reproduce. Inaccurate characterization can, in turn, significantly impact reported rates and patterns of relapse. 31 Salvage mastectomy has been the most common treatment approach for patients recurring after BCT and has resulted in local control rates in the range of 90%. 32 However, the aggressiveness with which additional salvage measures need to be approached following an IBTR continues to be the subject of much debate. [33] [34] [35] [36] Specifically, the subset of patients with an IBTR who would potentially benefit from systemic treatment needs to be accurately identified. 1 Because an IBTR classified as a recurrence of the index lesion is frequently associated with the development of metastatic disease (generally considered incurable), whereas a second independent primary tumor is treated with intent to cure, a more accurate classification of an IBTR could have a profound impact on patient care. 30 As a result, establishing the exact type of IBTR is critical in (1) helping to define the most optimal treatment strategy for a patient that develops an IBTR and (2) preventing the incorrect application of potentially toxic (and perhaps minimally effective) therapies.
Patterns of IBTR Over Time
In this analysis, a total of 57 isolated IBTRs were studied, of which 34 (60%) were classified as clonally related and 23 (40%) as clonally distinct. Table 4 clearly shows how the type of IBTR changes over time after the completion of BCT (mentioned in Fig.  1 ). These data are broadly consistent with prior published reports (including our own series) in that the frequency of E failures (clonally distinct) increases with time from completion of treatment. 37 However, it should also be noted that a thorough review of published data suggests that the cumulative incidence of E failures generally increases as the number of nonmolecular classification criteria employed increases. This suggests that considerable confusion still remains as to the most optimal means of clinically defining the type of IBTR and that more accurate and reproducible methods should be considered and developed. It is not insignificant that 44% of IBTRs were classified incorrectly using clinical criteria in this analysis even employing all other available tools.
Underscoring the importance of this is the percentage of neoplasms, either clonally related or clonally distinct, arising after a period of 10 years or greater (Fig. 1) . Similar findings were observed in the 20-year follow-up of the NSABP B-06 trial, in which 31% of recurrences in the lumpectomy ϩ RT arm were detected after 10 years. 38 The majority of IBTRs reported in the 2005 Early Breast Cancer Trialists' Collaborative Group 2005 meta-analysis update occurred within 5 years, although ipsilateral events continued to develop after 10 years of follow-up. 39 Attempting to clinically classify these delayed recurrences undoubtedly leads to a disproportionate number of E failures. Molecular classification is of great utility in these instances, potentially identifying a clonally related subgroup that would benefit from more aggressive salvage therapy rather than mastectomy alone.
Local Management Considerations for Breast Cancer
Accurately establishing the type of IBTR is critically important in helping to define useful criteria for optimizing local control after BCT, and in defining the efficacy of APBI compared with WBI. Since the rate of IBTR is generally quite low regardless of the form of BCT, the incorrect classification of even a small number of these recurrences may lead to invalid assumptions of treatment efficacy. This is of utmost importance for the accurate interpretation of data derived from clinical trials currently in accrual, such as the NSABP B-39/RTOG 0413 phase III trial comparing WBI versus APBI. The incorrect classification of IBTRs in this particular trial could potentially result in an invalid conclusion on the role of WBI in eradicating and/or preventing the development of other cancers in areas of the breast unrelated to the index lesion.
Moreover, molecular clonality assays should be employed to better identify factors associated with local recurrence after standard WBI. Historically, there have been inconsistent conclusions generated from treatment data exploring the association of several variables (margin status, radiation dose, extent of surgical resection, use of systemic chemotherapy, etc) on the risk of local recurrence after BCT. A portion of these inconsistencies could easily be attributed to the incorrect classification of even a small number of IBTRs. Since over 40% of clinical classifications of the type of IBTR were incorrect in our current study, we support that molecular clonality assays should be used in studies assessing variables associated with treatment efficacy.
Study Limitations
The cases included in this analysis did not constitute a series of consecutive IBTRs, due in large part to the condition of the tissue blocks. Thus, the cases analyzed are subject to a certain degree of selection bias. Despite this, the results are reasonable in light of the fact that the 57 IBTRs were accrued during an extended period of time from a large pool of comparable cases. Additional studies with even larger sample sizes are needed to further validate and expound upon these observations. However, the strength of this work is that it represents the largest accumulation of genetically studied IBTRs at a single institution from patients who were treated in a consistent manner. Allelic Imbalance Assays and IBTR Clonality
